CK Life Sciences Int'l., (Holdings) Inc. filed its Monthly Return for the period ended 30 September 2026, confirming that there were no changes in either authorised or issued share capital during the month.

Authorised Capital • Authorised share count remained at 15.00 billion ordinary shares with a par value of HKD 0.10, equivalent to HKD 1.50 billion in authorised capital. No increase or decrease was recorded.

Issued Shares and Treasury Position • Issued shares (excluding treasury shares) stood stable at 9.61 billion. • The company reported no treasury shares on its balance sheet, and there were no share issuances, repurchases, or cancellations.

Public Float Compliance • CK Life Sciences confirmed compliance with the Hong Kong Main Board’s minimum public-float requirement of 25% as of 30 September 2026.

Capital-Raising Instruments • The company reported no outstanding or newly issued share options, warrants, convertible securities, or other agreements that could dilute existing shareholders.

Governance Note • The Monthly Return was submitted to Hong Kong Exchanges and Clearing Limited on 5 October 2026 and signed by Company Secretary Eirene Yeung, affirming the accuracy of the reported figures.

Key Takeaway CK Life Sciences entered the fourth quarter of 2026 with a stable capital base, unchanged share count, and full compliance with public-float requirements, indicating no dilution pressures for existing shareholders during September.